-
1
-
-
33751533892
-
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors
-
Michalik, L.; Auwerx, J.; Berger, J. P.; Chatterjee, V. K.; Glass, C. K.; Gonzalez, F. J.; Grimaldi, P. A.; Kadowaki, T.; Lazar, M. A.; O'Rahilly, S.; Palmer, C. N.; Plutzky, J.; Reddy, J. K.; Spiegelman, B. M.; Staels, B.; Wahli, W. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol. Rev., 2006, 58, 726-741.
-
(2006)
Pharmacol. Rev.
, vol.58
, pp. 726-741
-
-
Michalik, L.1
Auwerx, J.2
Berger, J.P.3
Chatterjee, V.K.4
Glass, C.K.5
Gonzalez, F.J.6
Grimaldi, P.A.7
Kadowaki, T.8
Lazar, M.A.9
O'Rahilly, S.10
Palmer, C.N.11
Plutzky, J.12
Reddy, J.K.13
Spiegelman, B.M.14
Staels, B.15
Wahli, W.16
-
2
-
-
0036183630
-
The mechanisms of action of PPARs
-
Berger, J.; Moller, D. E. The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
-
(2002)
Annu. Rev. Med.
, vol.53
, pp. 409-435
-
-
Berger, J.1
Moller, D.E.2
-
3
-
-
32644460092
-
From molecular action to physiological outputs: Peroxisome proliferator- activated receptors are nuclear receptors at the crossroads of key cellular functions
-
Feige, J. N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: peroxisome proliferator- activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res., 2006, 45, 120-159
-
(2006)
Prog. Lipid Res.
, vol.45
, pp. 120-159
-
-
Feige, J.N.1
Gelman, L.2
Michalik, L.3
Desvergne, B.4
Wahli, W.5
-
4
-
-
0025132245
-
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
-
Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, (6294), 645-650.
-
(1990)
Nature
, vol.347
, Issue.6294
, pp. 645-650
-
-
Issemann, I.1
Green, S.2
-
5
-
-
34547604561
-
Transcription coactivators for peroxisome proliferator-activated receptors
-
Yu, S.; Reddy, J. K. Transcription coactivators for peroxisome proliferator-activated receptors. Biochim. Biophys. Acta, 2007, 1771, 936-951.
-
(2007)
Biochim. Biophys. Acta.
, vol.1771
, pp. 936-951
-
-
Yu, S.1
Reddy, J.K.2
-
6
-
-
60549090856
-
Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth
-
Marlow, L. A.; Reynolds, L. A.; Cleland, A. S.; Cooper, S. J.; Gumz, M. L.; Kurakata, S.; Fujiwara, K.; Zhang, Y.; Sebo, T.; Grant, C.; McIver, B.; Wadsworth, J. T.; Radisky, D. C.; Small ridge, R. C.; Copland, J. A. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res., 2009, 69, 1536-1544.
-
(2009)
Cancer Res
, vol.69
, pp. 1536-1544
-
-
Marlow, L.A.1
Reynolds, L.A.2
Cleland, A.S.3
Cooper, S.J.4
Gumz, M.L.5
Kurakata, S.6
Fujiwara, K.7
Zhang, Y.8
Sebo, T.9
Grant, C.10
McIver, B.11
Wadsworth, J.T.12
Radisky, D.C.13
Small Ridge, R.C.14
Copland, J.A.15
-
7
-
-
0028321529
-
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors
-
Kliewer, S.A.; Forman, B.M.; Blumberg, B.; Ong, E.S.; Borgmeyer, U.; Mangelsdorf, D.J.; Umesono, K.; Evans, R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA., 1994, 91:7355-7359
-
(1994)
Proc Natl Acad Sci USA
, vol.91
, pp. 7355-7359
-
-
Kliewer, S.A.1
Forman, B.M.2
Blumberg, B.3
Ong, E.S.4
Borgmeyer, U.5
Mangelsdorf, D.J.6
Umesono, K.7
Evans, R.M.8
-
8
-
-
16644370608
-
Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands
-
Miyachi, H. Design and synthesis of subtype- and species-selective peroxisome proliferator-activated receptor (PPAR) alpha ligands. Yakugaku Zasshi. 2004,124: 803-813.
-
(2004)
Yakugaku Zasshi
, vol.124
, pp. 803-813
-
-
Miyachi, H.1
-
9
-
-
0026785388
-
Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids
-
Schmidt, A.; Endo, N.; Rutledge, S. J.; Vogel, R.; Shinar, D.; Rodan, G. A. Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids. Mol. Endocrinol., 1992, 6, 1634-1641.
-
(1992)
Mol. Endocrinol.
, vol.6
, pp. 1634-1641
-
-
Schmidt, A.1
Endo, N.2
Rutledge, S.J.3
Vogel, R.4
Shinar, D.5
Rodan, G.A.6
-
10
-
-
4744340732
-
Impact of genetic variation of PPARgamma in humans
-
Meirhaeghe, A.; Amouyel, P. Impact of genetic variation of PPARgamma in humans. Mol. Genet. Metab., 2004, 83, 93-102.
-
(2004)
Mol. Genet. Metab.
, vol.83
, pp. 93-102
-
-
Meirhaeghe, A.1
Amouyel, P.2
-
11
-
-
10044291717
-
The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity
-
Buzzetti, R.; Petrone, A.; Ribaudo, M. C.; Alemanno, I.; Zavarella, S.; Mein, C. A.; Maiani, F.; Tiberti, C.; Baroni, M. G.; Vecci, E.; Arca, M.; Leonetti, F.; Di Mario, U. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur. J. Hum. Genet., 2004, 12, 1050-1054.
-
(2004)
Eur. J. Hum. Genet.
, vol.12
, pp. 1050-1054
-
-
Buzzetti, R.1
Petrone, A.2
Ribaudo, M.C.3
Alemanno, I.4
Zavarella, S.5
Mein, C.A.6
Maiani, F.7
Tiberti, C.8
Baroni, M.G.9
Vecci, E.10
Arca, M.11
Leonetti, F.12
Di Mario, U.13
-
12
-
-
36549038966
-
PPAR agonists: Multimodal drugs for the treatment of type-2 diabetes
-
Gross, B.; Staels, B. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 687-710.
-
(2007)
Best Pract. Res. Clin. Endocrinol. Metab.
, vol.21
, pp. 687-710
-
-
Gross, B.1
Staels, B.2
-
13
-
-
77955057772
-
PARα: An emerging therapeutic target in diabetic microvascular damage
-
Hiukka, A., Maranghi, M., Matikainen, N., Taskinen, M.R. PARα: an emerging therapeutic target in diabetic microvascular damage. Nature Rev. Endocrinol., 2010, 6, 454-463.
-
(2010)
Nature Rev. Endocrinol.
, vol.6
, pp. 454-463
-
-
Hiukka, A.1
Maranghi, M.2
Matikainen, N.3
Taskinen, M.R.4
-
14
-
-
33845962552
-
Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids
-
Brunmair, B.; Staniek, K.; Dorig, J.; Szocs, Z.; Stadlbauer, K.; Marian, V.; Gras, F.; Anderwald, C.; Nohl, H.; Waldhausl, W.; Furnsinn, C. Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia 2006, 49, 2713-2722.
-
(2006)
Diabetologia
, vol.49
, pp. 2713-2722
-
-
Brunmair, B.1
Staniek, K.2
Dorig, J.3
Szocs, Z.4
Stadlbauer, K.5
Marian, V.6
Gras, F.7
Anderwald, C.8
Nohl, H.9
Waldhausl, W.10
Furnsinn, C.11
-
15
-
-
34548182594
-
PPAR dual agonists: Are they opening Pandora's Box?
-
Balakumar, P.; Rose, M.; Ganti, S. S.; Krishan, P.; Singh, M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol. Res., 2007, 56, 91-98.
-
(2007)
Pharmacol. Res.
, vol.56
, pp. 91-98
-
-
Balakumar, P.1
Rose, M.2
Ganti, S.S.3
Krishan, P.4
Singh, M.5
-
16
-
-
33750511973
-
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome
-
Fievet, C.; Fruchart, J. C.; Staels, B. PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. Curr. Opin. Pharmacol., 2006, 6, 606-614.
-
(2006)
Curr. Opin. Pharmacol.
, vol.6
, pp. 606-614
-
-
Fievet, C.1
Fruchart, J.C.2
Staels, B.3
-
17
-
-
34547661571
-
Peroxisome proliferatoractivated receptor structures: Ligand specificity, molecular switch and interactions with regulators
-
Zoete, V.; Grosdidier, A.; Michielin, O. Peroxisome proliferatoractivated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim. Biophys. Acta, 2007, 1771, 915-925.
-
(2007)
Biochim. Biophys. Acta.
, vol.1771
, pp. 915-925
-
-
Zoete, V.1
Grosdidier, A.2
Michielin, O.3
-
18
-
-
33745957332
-
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study
-
Kendall, D. M.; Rubin, C. J.; Mohideen, P.; Ledeine, J. M.; Belder, R.; Gross, J.; Norwood, P.; O'Mahony, M.; Sall, K.; Sloan, G.; Roberts, A.; Fiedorek, F. T.; DeFronzo, R. A. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care, 2006, 29, 1016-1023.
-
(2006)
Diabetes Care
, vol.29
, pp. 1016-1023
-
-
Kendall, D.M.1
Rubin, C.J.2
Mohideen, P.3
Ledeine, J.M.4
Belder, R.5
Gross, J.6
Norwood, P.7
O'Mahony, M.8
Sall, K.9
Sloan, G.10
Roberts, A.11
Fiedorek, F.T.12
Defronzo, R.A.13
-
19
-
-
28144451163
-
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus
-
Nissen, S. E.; Wolski, K.; Topol, E. J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA, 2005, 294, 2581-2586.
-
(2005)
JAMA
, vol.294
, pp. 2581-2586
-
-
Nissen, S.E.1
Wolski, K.2
Topol, E.J.3
-
20
-
-
33947410702
-
The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice
-
Tozzo, E.; Ponticiello, R.; Swartz, J.; Farrelly, D.; Zebo, R.; Welzel, G.; Egan, D.; Kunselman, L.; Peters, A.; Gu, L.; French, M.; Chen, S.; Devasthale, P.; Janovitz, E.; Staal, A.; Harrity, T.; Belder, R.; Cheng, P. T.; Whaley, J.; Taylor, S.; Hariharan, N. The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice. J. Pharmacol. Exp. Ther., 2007, 321, 107-15.
-
(2007)
J. Pharmacol. Exp. Ther.
, vol.321
, pp. 107-115
-
-
Tozzo, E.1
Ponticiello, R.2
Swartz, J.3
Farrelly, D.4
Zebo, R.5
Welzel, G.6
Egan, D.7
Kunselman, L.8
Peters, A.9
Gu, L.10
French, M.11
Chen, S.12
Devasthale, P.13
Janovitz, E.14
Staal, A.15
Harrity, T.16
Belder, R.17
Cheng, P.T.18
Whaley, J.19
Taylor, S.20
Hariharan, N.21
more..
-
21
-
-
35248816864
-
Tesaglitazar, a dual peroxisome proliferator- activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice
-
Chira, E. C.; McMillen, T. S.; Wang, S.; Haw, A., 3rd; O'Brien, K. D.; Wight, T. N.; Chait, A. Tesaglitazar, a dual peroxisome proliferator- activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis, 2007, 195, 100-109.
-
(2007)
Atherosclerosis
, vol.195
, pp. 100-109
-
-
Chira, E.C.1
McMillen, T.S.2
Wang, S.3
Haw 3rd, A.4
O'Brien, K.D.5
Wight, T.N.6
Chait, A.7
-
22
-
-
33646269938
-
Tesaglitazar: A promising approach in type 2 diabetes
-
Cox, S. L. Tesaglitazar: a promising approach in type 2 diabetes. Drugs Today (Barc), 2006, 42, 139-146.
-
(2006)
Drugs Today (Barc)
, vol.42
, pp. 139-146
-
-
Cox, S.L.1
-
23
-
-
70350547900
-
Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats
-
Liao, J.; Soltani, Z.; Ebenezer, P.; Isidro-Carrion, A. A.; Zhang, R.; Asghar, A.; Aguilar, E.; Francis, J.; Hu, X.; Ferder, L.; Reisin, E., Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. Nephron Exp. Nephrol., 2010, 114, e61-68.
-
(2010)
Nephron Exp. Nephrol.
, vol.114
-
-
Liao, J.1
Soltani, Z.2
Ebenezer, P.3
Isidro-Carrion, A.A.4
Zhang, R.5
Asghar, A.6
Aguilar, E.7
Francis, J.8
Hu, X.9
Ferder, L.10
Reisin, E.11
-
24
-
-
34547559826
-
Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice
-
Cha, D. R.; Zhang, X.; Zhang, Y.; Wu, J.; Su, D.; Han, J. Y.; Fang, X.; Yu, B.; Breyer, M. D.; Guan, Y. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes, 2007, 56, 2036-2045.
-
(2007)
Diabetes
, vol.56
, pp. 2036-2045
-
-
Cha, D.R.1
Zhang, X.2
Zhang, Y.3
Wu, J.4
Su, D.5
Han, J.Y.6
Fang, X.7
Yu, B.8
Breyer, M.D.9
Guan, Y.10
-
25
-
-
34447547870
-
Tesaglitazar, a PPARalpha/ gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats
-
Hellmold, H.; Zhang, H.; Andersson, U.; Blomgren, B.; Holland, T.; Berg, A. L.; Elebring, M.; Sjogren, N.; Bamberg, K.; Dahl, B.; Westerberg, R.; Dillner, B.; Tugwood, J.; Roberts, R.; Lundholm, E.; Camejo, G.; Skanberg, I.; Evans, J. Tesaglitazar, a PPARalpha/ gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. Toxicol. Sci., 2007, 98, 63-74.
-
(2007)
Toxicol. Sci.
, vol.98
, pp. 63-74
-
-
Hellmold, H.1
Zhang, H.2
Andersson, U.3
Blomgren, B.4
Holland, T.5
Berg, A.L.6
Elebring, M.7
Sjogren, N.8
Bamberg, K.9
Dahl, B.10
Westerberg, R.11
Dillner, B.12
Tugwood, J.13
Roberts, R.14
Lundholm, E.15
Camejo, G.16
Skanberg, I.17
Evans, J.18
-
26
-
-
26844565049
-
Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo
-
Oleksiewicz, M. B.; Thorup, I.; Nielsen, H. S.; Andersen, H. V.; Hegelund, A. C.; Iversen, L.; Guldberg, T. S.; Brinck, P. R.; Sjogren, I.; Thinggaard, U. K.; Jorgensen, L.; Jensen, M. B. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol. Pathol., 2005, 33, 552-560.
-
(2005)
Toxicol. Pathol.
, vol.33
, pp. 552-560
-
-
Oleksiewicz, M.B.1
Thorup, I.2
Nielsen, H.S.3
Andersen, H.V.4
Hegelund, A.C.5
Iversen, L.6
Guldberg, T.S.7
Brinck, P.R.8
Sjogren, I.9
Thinggaard, U.K.10
Jorgensen, L.11
Jensen, M.B.12
-
27
-
-
26844499207
-
Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo
-
Egerod, F. L.; Nielsen, H. S.; Iversen, L.; Thorup, I.; Storgaard, T.; Oleksiewicz, M. B. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers, 2005, 10, 295-309.
-
(2005)
Biomarkers
, vol.10
, pp. 295-309
-
-
Egerod, F.L.1
Nielsen, H.S.2
Iversen, L.3
Thorup, I.4
Storgaard, T.5
Oleksiewicz, M.B.6
-
28
-
-
33745606757
-
The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats
-
Li, P. P.; Shan, S.; Chen, Y. T.; Ning, Z. Q.; Sun, S. J.; Liu, Q.; Lu, X. P.; Xie, M. Z.; Shen, Z. F. The PPARalpha/gamma dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats. Br. J. Pharmacol., 2006, 148, 610-618.
-
(2006)
Br. J. Pharmacol.
, vol.148
, pp. 610-618
-
-
Li, P.P.1
Shan, S.2
Chen, Y.T.3
Ning, Z.Q.4
Sun, S.J.5
Liu, Q.6
Lu, X.P.7
Xie, M.Z.8
Shen, Z.F.9
|